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1,3-Diacylglycerol is known to reduce body weight and fat deposits in humans. α-Lipoic acid is a potent antioxidant and eﬀective
against many pathological conditions, including obesity and related metabolic syndromes. The present work is based on the
hypothesis that the hybrid molecules of 1,3-diacylglycerol and lipoic acid possess synergistic and/or additive eﬀects compared
with the parent compounds against obesity, overweight, and related metabolic syndromes. Laboratory scale synthesis of 1,3-
dioleoyl-2-lipoyl-sn-glycerol (yield 80%) and 1,3-dioleoyl-2-dihydrolipoyl-sn-glycerol (yield 70%) was performed for the ﬁrst
time and supported by NMR and MS data. Free radical scavenging capacity of the conjugates was assayed using DPPH test. A
remarkably high in vitro free radical scavenging capacity was demonstrated for the 1,3-dioleoyl-2-dihydrolipoyl-sn-glycerol (EC50
value 0.21). RP-HPLC-MS-APCI analysis showed satisfactory separation between the conjugates (R∼1). Protonated molecular ion
of the conjugates at m/z 809 and m/z at 811, respectively, and their characteristic fragment ions were abundant.
1.Introduction
As predicted by WHO, by 2015, approximately 2.3 billion
adults will be overweight and more than 700 million will
be obese [1]. The multitudinous pathological consequences
of obesity and overweight include type II diabetes, oxida-
tive stress, inﬂammation, cardiovascular diseases, hyper-
lipidemia, and hypertension. The emerging global public
health issues of obesity, overweight, and related syndromes
need to be addressed urgently with multiple strategies and
approaches.
The triacylglycerol (TAG) content in edible fats and oils
generally exceeds 95%. Although a minor component, the
levels of diacylglycerol (DAG) can be as much as ca. 10%,
in some type of edible oils [2]. Figure 1 shows the chemical
structures of TAG and DAG molecules. 1,3-DAG is mainly
utilized by the body as a lean body mass energy source (or a
direct or instant energy source) rather than being stored in
the adipose tissue, in contrast to TAG, due to the diﬀerent
metabolic fates after absorption into the gastrointestinal
epithelial cells [2]. Clinical studies with animals and humans
on the eﬀects of DAG oil have shown that it signiﬁcantly
decreases body weight, suppresses body fat accumulation,
and lowers postprandial serum TAG levels, thus reducing
obesity-related health risks [3, 4]. The mechanism causing
the antiobesity eﬀects of DAG is not clearly understood,
and several pathways are suggested. After digestion, 1,3-
DAG is converted into 1-(or 3-) monoacylglycerol (MAG),
glycerol, and free fatty acids by the 1,3-lipases, in contrast
to TAG, which produces 2-MAG and free fatty acids. In the
epithelial cells of small intestines, 1- or 3-MAG is utilized
poorly for the resynthesis of TAG because of the preference
of DAG acyltransferase for the 2-MAG as a substrate. The
free fatty acids generated from 1,3-DAG are shunted directly2 Journal of Lipids
to the liver through the portal vein to be oxidized [2–4].
Theincreasedβ-oxidationresultsindecreasedfoodintakeby
increasing satiety and subsequently reduces body weight [2,
5].Itisalsosuggestedthatametaboliteof1,3-DAGisutilized
which follows an α-glycerophosphate pathway, in contrast to
TAG metabolites [6].Aserotonin-linked mechanismhasalso
been proposed for DAG-mediated promotion of negative
caloric balance, based on a study on Caco-2 cells with 1-
MAG, a digestive product of DAG. Enhanced expression of
genes associated with β-oxidation, fatty acid metabolism,
and thermogenesis, in concomitance with an increase in the
serotonin release from the Caco-2 cells, were reported [7].
The safety of dietary 1,3-DAG has been extensively studied,
and it is considered to be as safe as other edible oils [8, 9].
Naturally occurring α-lipoic acid (LA) is the dextro-
rotatory isomer of 5-(dithiolane)-pentanoic acid [10]. The
antioxidant properties of the LA and its reduced form
dihydrolipoic acid (DHLA) system for scavenging of the
reactive oxygen species (ROS), chelating metal ions, and
regenerating cellular antioxidants have been extensively
investigated [11, 12]. DHLA possesses superior antioxidant
properties compared with LA. It has been suggested that
both of these compounds are useful in the prevention and
treatment of obesity and overweight, as well as a variety
of pathological conditions linked to oxidative stress, for
example, diabetes and cardiovascular disease, liver diseases,
AIDS, and age-related disorders, [11–13] .L Ah a sb e e ni nu s e
as a supplement and is popularly known as the “metabolic
antioxidant” or “the universal antioxidant” [11, 14].
The most important function of LA is as a cofactor of
mitochondrial enzymes in energy metabolism. The redox
pair LA/DHLA are highly eﬀective against reactive oxygen
species (ROS) and reactive nitrogen species (RNS). In
additiontoitsantioxidantfunctionbydirectradicaltrapping
and/or metal chelation, LA also modulates important signal
transduction pathways that increase the endogenous cellular
antioxidants, for example, glutathione (GSH), and lower
inﬂammatory and antiapoptotic signalling pathways [15].
Supplementation of LA (800mg/d) for four months showed
signiﬁcant body weight reduction: 8% in preobese and 9%
in obese human subjects. The authors have suggested that
LA may be an ideal candidate for treatment of obesity
and related diseases [16]. It has been shown in rats that
the reason for the considerable weight loss caused by
LA acid is the suppression of hypothalamic adenosine
monophosphate-activated protein kinase (AMPK) activity,
resulting in enhanced energy expenditure. These eﬀects
were neither due to systemic toxicity nor dependent on
leptin and its receptor [17]. Further, the authors found
that LA increases glucose uptake and fatty acid oxidation
by increasing AMPK in skeletal muscle, in contrast to its
eﬀects in the hypothalamus, and acts diﬀerently depending
on the tissue types. Humans can tolerate several grams of LA
administered orally without any adverse eﬀect [18, 19].
The conventional antiobesity drugs generally have
adverse side eﬀects and are not eﬀective in eliminating the
main cause of obesity [20]. Extensive research is at present
being conducted on low-energy diets and very-low-energy
diets (VLEDs) in the management of body weight, obesity,
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Figure 1: Chemical structures of triacylglycerol (TAG) and diacyl-
glycerols (DAG) wherein R1,R 2, and R3 are an alkyl or an alkenyl,
hydrocarbon chain of a fatty acid (general formula R-COOH)
esteriﬁed on the glycerol backbone.
and related pathological syndromes. Weight reduction by
more than 15kg can be achieved by VLED after 8 weeks, but
maintaining this loss of weight during a longer period is dif-
ﬁcultandthatrequiresacombinationofweightmaintenance
strategies [21]. A multitude of LA conjugates have been
synthesized in order to enhance stability and the biological
and functional properties of the parent components and/or
t oa c h i e v ed u a lf u n c t i o n s[ 22–24].
This study is based on the hypothesis that the novel
hybrids of DAG with LA and DHLA possess advantages
compared with the parent compounds due to synergistic
and/or cumulative eﬀects. It is anticipated that these hybrid
molecules can be used as functional food and/or novel ingre-
dients and may open a new research area for their potential
weight loss and antioxidant functions. In an acutepilot study
in Wistar rats using a single dose of 200mg/kg, both DOLA
and DODHLA seemed to reduce food intake after 4 hours
compared to control vehicle (unpublished results). The
resultspromptedustoconductthepresentstudy,andfurther
feeding experiments are being pursued. As the ﬁrst part of
the study, we report here on the synthesis of 1,3-dioleoyl-2-
lipoyl-sn-glycerol(DOLA)and1,3-dioleoyl-2-dihydrolipoyl-
sn-glycerol (DODHLA) hybrids [25]. In addition, in vitro
DPPH-based free radical scavenging capacity and RP-HPLC-
MS-APCI evaluations of the hybrid compounds are also
presented.
2.MaterialsandMethods
2.1. General Procedure and Materials. 1,3-Dioleoyl-sn-
glycerol from Nu-Check Prep, Inc., (Elysian, MN, USA) and
LA were purchased from Sigma-Aldrich AB (Stockholm,
Sweden). The chemicals and solvents, unless otherwise
speciﬁed in the syntheses of the compounds in the examples,
were purchased from VWR International AB (Stockholm,
Sweden). The chromatographic separations were performed
using silica gel (60 ˚ A, 200–400mesh). The compounds
were analyzed by TLC: silica plates (Merck 60), and the
compounds were visualized by treatment with a 10%Journal of Lipids 3
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Figure 2: Scheme showing the structures and syntheses of 1,3-dioleoyl-2-lipoyl-sn-glycerol (DOLA, 1) and 1,3-dioleoyl-2-dihydrolipoyl-sn-
glycerol (DODHLA, 2).
solution of phosphomolybdic acid (PMA) in ethanol
followed by heating. 1H, 13C NMR, and 2D experiments
(COSY and HSQC-dept) spectra were obtained on a Bruker
400MHz spectrometer (Bruker DRX, Germany), and
chemical shifts (δ) are given in ppm relative to TMS. The
spectra were recorded in CDCl3 as the solvent at 30◦C.
2.2. Preparation of 1,3-Dioleoyl-2-lipoyl-sn-glycerol (1). The
synthesis of DOLA was performed following a published
method with some modiﬁcations [26]. To a solution of DAG
(1.61mmol) in CH2Cl2 (9mL) were added DMAP (42mg,
0.34mmol), LA (435mg, 2.11mmol), and EDCI (310mg,
1.62mmol) at 0◦C with stirring. The reaction mixture was
stirredatroomtemperatureovernight.Anextractiveworkup
(CH2Cl2, dilute HCl, water, aqueous saturated NaCl) and
drying (Na2SO4) of the combined organic extracts and
concentration furnished the crude, which was puriﬁed by
chromatography to give the pure compound, no trace of
cis/trans isomerisation was observed by NMR analysis (1H,
COSY, and HSQC-dept): 1,3-dioleoyl-2-lipoyl-sn-glycerol
(1) (structure shown in Figure 2): (1g, 80%). 1HN M R
(CDCl3, 400MHz), (δ) 5.45–5.30 (m, 4H), 5.28–5.20 (m,
1H), 4.35–4.25 (dd, 2H), 4.18–4.10 (dd, 2H), 3.60–3.50 (m,
1H), 3.21–3.06 (m, 2H), 2.50–2.40 (m, 1H), 2.35–2.28 (m,
6H), 2.05–1.96 (m, 8H), 1.95–1.85 (m, 1H), 1.75–1.56 (m,
8H), 1.55–1.40 (m, 2H), 1.39–1.20 (m, 40H), 0.92–0.85 (t,
6H).13CN M R( C D C l 3, 100MHz), (δ) 173.2, 172.5, 130.0,
129.7, 69.1, 62.0, 56.3, 40.2, 38.5, 34.6, 34.0, 33.9, 31.9, 29.8,
29.7, 29.5, 29.4, 29.3, 29.2, 29.1, 29.0, 28.7, 27.3, 27.2, 24.8,
24.6, 22.7, 14.1.
2.3.Preparationof1,3-Dioleoyl-2dihydrolipoyl-sn-glycerol(2).
The synthesis of DODHLA was conducted following a
published method with some modiﬁcations [27]. DOLA
(0.247mmol) was dissolved in CH2Cl2/MeOH (1:5, v/v,
12mL) under N2. NaBH4 (14mg, 0.371mmol) was added
in portions, and the reaction mixture was stirred at room
temperature under N2 (Figure 2). After about 2h, aque-
ous 1MHCl (5mL) was added. An extractive workup
(CH2Cl2, dilute HCl, water, aqueous saturated NaCl) and
drying (Na2SO4) of the combined organic extracts and
concentration furnished the crude, which was puriﬁed by
chromatography to give the pure compound, no trace of
cis/trans isomerisation was observed in NMR analysis: 1,3-
dioleoyl-2Dihydrolipoyl-sn-glycerol (2): (140mg, 70%). 1H
NMR (CDCl3, 400MHz), (δ) 5.43–5.35 (m, 4H), 5.30–5.25
(m, 1H), 4.36–4.25 (dd, 2H), 4.20–4.12 (dd, 2H), 3.01–2.90
(m, 1H), 2.80–2.65 (m, 2H), 2.40–2.30 (m, 6H), 2.10–1.86
(m, 9H), 1.80–1.45 (m, 11H), 1.40–1.20 (m, 42H), 0.95–
0.86 (t, 6H). 13C NMR (CDCl3, 100MHz), (δ) 173.2, 172.5,
130.0, 129.7, 69.1, 62.0, 42.8, 39.3, 38.7, 34.2, 34.0, 31.9, 29.8,
29.7, 29.6, 29.5, 29.4, 29.3, 29.2, 29.1, 27.2, 27.1, 26.6, 24.8,
24.5, 22.7, 22.3, 14.1.
2.4. Evaluation of Free Radical Scavenging Capacity. The in
vitro free radical scavenging capacity of the test compounds4 Journal of Lipids
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Figure 3: DPPH radical reduction (%) as a function of molar ratio of (a) LA/DPPH free radical; (b) DHLA/DPPH free radical; (c)
DOLA/DPPH free radical; (d) DODHLA/DPPH free radical.
Table 1: Free radical scavenging activity of DHLA and DODHLA.
Compound Eﬃcient concentration
(EC50)a ± SD
Antradical power
(ARP)b ±SD
No. moles DPPH reduced/mole
of antioxidant ±SD
DHLA 0.39 ± 0.04 2.56 ± 0.24 1.28 ± 0.12
DODHLA 0.22 ± 0.03 4.55 ± 0.55 2.27 ± 0.27
DHLA: dihydrolipoic acid; DODHLA: 1,3-dioleoyl-2Dihydrolipoyl-sn-glycerol.
aEﬃcient Concentration = EC50.
bARP value was calculated from 1/ EC50, the larger the ARP the more eﬃcient the antioxidant (see [29]).
was determined according to the DPPH (2,2Diphenyl-1-
1picrylhydrazyl) method [28, 29]. Molar ratios between
sample and DPPH in ﬁnal mixture, from 1 to 8 in triplicates,
were tested for α-LA and 1,-3-DOLA, while molar ratios
from 0.05 to 1.2 were tested for DHLA and 1,3-DODHLA
at room temperature along with a reagent blank. In each
test 3.9mL of 0.06mM DPPH solution in toluene [30]
was mixed with 0.1mL of sample dissolved in toluene, and
absorbance was measured at 515nm at 15min intervals
until steady status was reached for the remaining DPPH
percentage. Mean value of at least three replicates for each
molar concentration along with error bars is presented
in Table 1 and in Figure 3. Antiradical activity deﬁned as
the amount of antioxidant necessary to decrease the initial
DPPH concentration by 50% (Eﬃcient Concentration =
EC50 (mol/L) and antiradical power (APR = 1/EC50)) [31]
value was calculated.
2.5. Thin-Layer Chromatography (TLC). The initial com-
pounds used in the synthesis, LA, DO and the synthesized
compounds DOLA and DODHLA were checked using TLC
(Si, 0.25mm). The optimal mobile phase mixture was
hexane:diethyl ether:ethyl acetate: acetic acid (75:20:5:1,
v/v/v/v). Approximately 20–30μg of the compounds were
spotted.TheplatewassprayedwithPMAandvisualizedafter
drying in an oven at 120◦C for 15min.Journal of Lipids 5
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Figure 4: RP-HPLC-MS-APCI total ion and retention time of
the test compounds. (a) LA; (b) DHLA; (c) DO; (d) DOLA; (e)
DODHLA (Table 2 is referred for abbreviations).
2.6. RP-HPLC-MS-APCI. An HPLC-MS (HP 1100 Series,
Agilent technologies Inc., Palo Alto, CA) equipped with a
quaternary gradient pump, thermostated column compart-
ment, thermostated autosampler, single quadrupole mass
analyzer (G 1946D), Chemstation Rev.B.04.01 software.
Chromatographic conditions were optimized based on the
LC method [31]. DOLA and DODHLA were separated using
a reversed phase Thermo Hypersil GOLD column, 150 ×
4.6mm i.d, 3μm particle size (Thermo Electron Corpora-
tion, UK). Mobile phase consisted of a tertiary mixture ace-
tonitrile:2-propanol:5mmolaqueousaceticacid(65:30:5,
v/v/v) was used for column equilibration. Gradient elution
was started with the same solvent mixture linearly changing
to (25:70:5, v/v/v) over a period of 30min. Flow rate was
maintained at 0.6mL/min, postrun equilibration time was
10min, and column temperature was set at 20◦C. Analytes
were dissolved in hexane ca.1-2μg/μL, and 1μL was injected.
APCI was performed as follows; vaporizer temperature
300◦C, drying gas ﬂow rate 9L/min and temperature 350◦C,
nebulizer pressure 60psi, corona current 8μA, capillary
voltage 3000V and fragmentor voltage at 70V. Total Ion
Current (TIC) was recorded in SCAN mode at a mass range
from m/z 100–1000.
3. Results
In Figure 2, the scheme on synthesis of the derivatives of 1,3-
dioleoyl-sn-glycerol with LA and DHLA is shown. We have
synthesized 1,3-DAG-lipoates only with oleic acid as a model
in this study. Certain optimization during synthesis and
preparative works using silica gel column chromatography
were necessary. The chemical synthesis was supported with
NMR data as shown in the methodology section.
Stable DPPH• is considered as suitable for analysis
performed at micromolar levels and for lipophilic com-
pounds [28–30]. The free radical scavenging capacity of
standard LA and DHLA was also evaluated with the same
method to compare the reduction potential of the test hybrid
compounds. The non-reduced compounds, LA and DOLA,
showed a comparatively low interaction with DPPH•. LA did
not interact with more than 98.2% of the initial DPPH• at
the highest tested molar ratio of 8, even after a longer time
of more than 5h. Similarly, at the same molar ratio, the
resultsforDOLAshowedthat92.3%oftheDPPH• remained
unchanged, indicating a free radical scavenging activity that
was slightly higher compared with LA (Figures 3(a) and
3(c)). Remarkably high free radical scavenging activity was
observed for the reduced compounds DHLA and DODHLA.
The time taken to reach the steady state varied from 20min
to2.5h,fortheconcentrationsexpressedasmolarratio0.05–
1.2 (Figures 3(b) and 3(d)). The interaction of the reduced
compounds with DPPH• was clearly dependent on both the
concentration and the time, in contrast to the corresponding
interaction of the nonreduced compounds. Similarly, the
remaining DPPH• measured for DHLA at molar ratio 1 was
14.4%, whereas that for DODHLA was 6.4%. The calculated
EC50 value for DODHLA was 0.21, while that for DHLA was
0.38 (Table 1).
RP-HPLC-MS-APCI total ion chromatograms of the test
compounds are shown in Figures 4(a)–4(e). The elution
orderwasrelatedtothepolarityofthecompounds.Themost
polar LA and DHLA were eluted ﬁrst followed by less polar
DO, DODHLA, and DOLA. Satisfactory separation among
the analyzed parent compounds and the conjugates except
L Aa n dD H L Aw e r ea c h i e v e d( Table 2, Figure 4), and the6 Journal of Lipids
Table 2:LinearformulaofLA,DHLA,DOLA,andDODHLA,retentiontime(RT,minutes),monoisotopicmassandHPLC-MS-APCIdata.
Compound RT (min) Monoisotopic mass Ions (m/z) Suggested molecular ions/fragments Relative intensity
of ions (%)
LAa
[C8H14O2S2]
3.47 206.04
205 [M–H]− [M–H]− 100
171 [M–34–H]− [M–H2S–H]− 6
411 [2M–H]− [2M–H]− 6
DHLAb
[C8H16O2S2]
3.46 208.06
207 [M–H]− [M–H]− 72
173 [M–34–H]− [M–H2S–H]− 3
205 [M–2H–H]− [M–2H–H]− 100
171 [M–2H–34–H]− [M–2H–H]− 15
DOc
[C39H72O5]
15.13 620.54
621 [M+H]+ [M+H]+ 3
603 [M–18+H]+ [M–H2O+H]+ 100
339 [M–282+H]+ [M–R1COOH+H]+ 80
DOLAd
[C47H84O6S2]
17.68 808.57
809 [M+H]+ [M+H]+ 100
603 [M–206+H]+ [M–R2COOH+H]+ 2
527 [M–282+H]+ [M–R1COOH+H]+ 7
339 [M–206–
282+18+H]+ [M–R1COOH–R2COOH+H2O+H]+ 3
826 [M+17+H]+ Unidentiﬁed adduct 7
DODHLAe
[C47H86O6S2]
17.05 810.59
811 [M+H]+ [M+H]+ 26
793 [M–18+H]+ [M–H2O+H]+ 15
603 [M–208+H]+ [M–R3COOH+H]+ 76
529 [M–282+H]+ [M–R1COOH+H]+ 100
339 [M–208–
282+18+H]+ [M–R3COOH–R1COOH+H2O+H]+ 35
828 [M+17+H]+ Unidentiﬁed adduct 13
aLA: α-lipoic acid; bDHLA: dihydro lipoic acid; cDO: 1,3-dioleoyl-sn-glycerol; dDOLA: 1,3-dioleoyl-2-lipoyl-sn-glycerol; eDODHLA: 1,3-dioleoyl-
2dihydrolipoyl-sn-glycerol;
∗R1COOH = oleic acid general formula; R2COOH = α-lipoic acid general formula; R3COOH = dihydrolipoic acid general formula.
calculated resolution between DOLA, and DODHLA was
acceptable (R∼1, results are not shown in Table). Due to
their acidic properties, LA and DHLA could only be ionized
in negative ion mode whereas DO, DOLA and DODHLA
were easily ionized in positive ion mode. The APCI mass
spectra, the major ions, and possible fragmentation pattern
of each compound analysed are shown in Figures 5(a)–5(e)
and Table 2. Deprotonated molecular ions [M–H]− were the
major ions observed for LA and DHLA with m/z 205 and
207, respectively. For DHLA the formation of [M–2H–H]−
ion was also observed at m/z 205.
In the mass spectrum for DO (Figure 5(c)) the major
ion observed was at m/z 603 [M+H-18]+. Ion fragment at
m/z 339 [M–RCOOH+H]+ showed dissociation of one oleic
acid moiety in DO resulting protonated MAG. Protonated
molecular ion at m/z 621 [M+H]+ was observed at very low
abundance. A protonated molecular ion at m/z 809 [M+H]+
with minimum fragmentation was observed in DOLA
(Figure 5(d)). Ion fragment at m/z 527 corresponding to one
dissociated oleic acid [M–R1COOH+H]+ was observed. The
ion fragment at m/z 339 [M–R1COOH–R2COOH+H2O]+
showed where an oleic acid and LA moiety were dissociated.
A similar fragment ion was observed in the mass spectrum
of DO albeit at much lower abundance. Ion fragment at
m/z 603 [M–R2COOH+H]+ was the least abundant ion
where only LA moiety was dissociated from the parent
molecule. DODHLA showed the most fragmentation among
all compounds tested where protonated molecular ion at
m/z 811 [M+H]+ appeared as only 40% of the base peak.
This may suggest that DOLA is possibly more stable than
DODHLA.
4. Discussion
1,3-DAG can be prepared with fatty acids from any fats, and
oils and the fatty acid composition would depend on the
substrate [32]. The physicochemical properties might vary
depending on the acyl moieties within the synthesized DAG
molecule. Fatty acids in 1,3-DAG are presumed to be utilized
mainly for energy formation [2, 3]. It is common approach
to synthesise new hybrid molecules with the anticipation
of synergistic and/or dual eﬀects due to their modiﬁed
physical, chemical, and biological eﬀects such as solubility
and bioavailability, compared with the parent molecules
[22, 24, 33, 34].
Studies have shown that obesity and metabolic syn-
drome-related pathological conditions such as hypertension,
insulin resistance, diabetes, and hyperlipidemia, are linked
with chronic inﬂammation and oxidative stress caused byJournal of Lipids 7
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Figure 5: APCI mass spectra recorded at negative mode (a-b) [M-H]− and recorded at positive ion mode (c–e) and the structures of the test
compounds. (a) LA; (b) DHLA; (c) DO; (d) DOLA; (e) DODHLA (Table 2 is referred for abbreviations).8 Journal of Lipids
the elevation of ROS and a lower antioxidant status. It is
also well established that obese subjects have higher levels
of oxidative stress biomarkers than leaner subjects [35, 36].
An antioxidant is generally deﬁned as any substance in
a low concentration, compared with a substrate, which
signiﬁcantly delays or prevents oxidation of the substrate.
Moreover it alone or in conjunction with another compo-
nent can act in diﬀerent ways for example, it can chelate
metal ions, reduce the eﬀects of ROS through its free radical
scavenging capacity, regenerate endogenous antioxidants,
play a role in repairing systems, inﬂuence gene expression,
and so forth, [18, 37–39]. The antioxidant activity of LA
has been extensively studied. In vitro DPPH• free radical
activity of LA and some LA-coumarin derivatives dissolved
in ethanol was studied previously [24]. We observed lower
a c t i v i t yf o rL At e s t e di nt o l u e n ec o m p a r e dt ot h a ts t u d y
solvent may have aﬀected the results. LA acts as an antioxi-
dant by scavenging hydroxy radicals, hypochlorous acid, and
singlet oxygen in multiple systems such as organic solvents,
as well as under physiological conditions. It is suggested that
this antioxidant activity is due to the strained conformation
of the 5-membered dithiolane ring in the intramolecular
disulﬁde form of LA.
In biological systems LA is reduced to DHLA, which has
been proved to be a more potent antioxidant. During trans-
ferring acyl groups bound to it from one part of the enzyme
complex to another, LA is reduced to DHLA and again
oxidized back to LA by lipoamide dehydrogenase forming
NADH, and thus LA and DHLA act as redox pair by carrying
electrons to NAD+ from the substrate of the dehydrogenase
[18, 38]. DHLA has stronger antioxidant activity due to
the two S-H groups and is readily oxidized back to 1,2-
thiolanes. It acts readily as a potent scavenger of reactive
oxygen species such as hydroxyl radicals, hypochlorous acid,
superoxide anion radicals, and peroxyl radicals. It has also
been suggested that DHLA may act as a prooxidant by the
reduction of transition metals [38, 39].
In our study DHLA showed lower DPPH• scavenging
capacity than DODHLA. This discrepancy may be due to
diﬀerences of the purity of these compounds as described
later. The EC50 values reported for antioxidant compounds
common in foods [29] were compared with the EC50 values
in this study (Table 1). The free radical scavenging capacity
observed for DODHLA indicates a similar capacity to that of
α-tocopherol, which is a fat-soluble antioxidant. In addition
to the structural conformation, the interaction between the
potential antioxidant and DPPH• can be inﬂuenced by the
polarity of the solvent, as well as the aﬃnity of the tested
compound towards the solvent [29]. Although it is expected
that one should at least obtain very similar EC50 values for
DHLA and DODHLA, in our study lower EC50 value was
observed for DHLA. This minor diﬀerence is probably due
to the fact that the commercial DHLA was not extremely
pure, which was detected when it was checked by TLC
in our laboratory. Looking at the close similarity in the
DPPH free radical scavenging behaviour between the two
pairs LA/DHLA and DOLP/DODHLA, it is reasonable to
speculate that this pair would exhibit a similar behaviour in
biological systems.
The mass spectral data observed for DO are completely
agreeable with the previous data for DAG analyzed by APCI
[40]. Since the hybrid molecules DOLA and DODHLA are
synthesized for the ﬁrst time in this study, there is no
literature to compare with their mass spectral data. The
diﬀerence observed in the mass for protonated molecular
ions of DOLA and DODHLA was corresponding to m/z 2
units conﬁrming the reduction of disulﬁde bond in the LA
which is given in literature as 2.02Da [41]. Major fragment
ion observed was at m/z 529 [M–R1COOH+H]+ where one
oleic acid moiety was dissociated from the molecule. The
two fragments at m/z 527 and m/z 529 were observed for
corresponding DAG ion in DOLA and DODHLA, which
further highlighted the reduction of disulﬁde bond in the
LA moiety. The common fragment ion at m/z 603 showed
dissociation of DHLA moiety from DODHLA, leaving DAG
ion with two oleic acids. The fragment at m/z 793 suggests
an ion [M–H2O+H]+. However, the ion fragment at m/z 626
in DOLA and at m/z 628 in DODHLA may be due to some
adduct formation in the mass analyser. Less fragmentation
observedin APCIcanalsobeattributedbyneutralmolecules
and fatty acid or carboxylic acid molecules formed during
ionisation because they are not visible in the mass spectrum.
The molecular ions and fragment ions at m/z 171 and
173 for LA and DHLA, respectively, as found in this study
were in agreement with earlier ﬁndings [42]. The formation
of [M–2H–H]− ion at m/z 205 was also observed, probably
due to dehydrogenation of dithiol group in [M–H]− ion at
high temperature, as it was suggested for methyl lipoate and
methyl dihydro lipoate analysed by using GC-MS [43]. It
is to be mentioned here that mass spectrum of DODHLA
also showed an ion at m/z 8 0 9b u ta tv e r yl o wi n t e n s i t y .T o
check the origin of these ions, we analysed newly synthesized
both DOLA and DODHLA by HPLC-MS, and it was found
that these compounds were separated from each other and
still DODHLA contained both the ions at m/z 809 (at a
very low abundance) and at m/z 811 as the major ion.
Further, it showed that the ion at m/z 809 also appears
at the same retention time as at m/z 811 while tracing
these ions at selective ion mode suggesting some possibility
of dehydrogenation of DODHLA into DOLP during the
ionization in the HPLC-MS interphase (results are not
shown). We performed HPLC-MS analyses of DODHLA
at diﬀerent vaporizer temperatures in MS 250, 300, 350,
400◦C while maintaining same drying gas temperature at
350◦C. Similar results were observed for area ratio when the
drying gas temperature was constant at 300◦Ca n dv a p o r i z e r
temperatures were changed from 250 to 400◦C. Considering
the results on the lowest peak area ratio between m/z at 811
and 809 and the noise level, it was decided to use 300◦C
as the vaporizer temperature and 350◦C as the drying gas
temperature in our method.
DPPH test provides evidence of a potential free radical
scavenging capacity; however, DPPH• is not similar to ROS
which occur naturally in biological systems. Further studies
are planned to evaluate the antiobesity and overweight
and in vitro and in vivo antioxidant properties of these
hybrid compounds. The analysis using APCI provided soft
fragmentation, yet informative mass spectra with protonatedJournal of Lipids 9
molecular ions and several fragment ions of the novel
compounds DOLA and DODHLA. These data would be
usefulinidentiﬁcationandquantiﬁcationoftheseconjugates
andpossiblemetabolitesinfutureinvitroandinvivostudies.
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